Tempus AI to Acquire Ambry Genetics for $600 Million

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <title> Tempus AI to Acquire Ambry Genetics for $600 Million </title> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <link rel="canonical" href="https://www.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/" />  <script async src="https://www.googletagmanager.com/gtag/js?id=G-YK7FCK71TD"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-YK7FCK71TD'); </script> <meta name="description" content="Tempus AI announced its acquisition of Ambry Genetics for $600 million, strengthening its genetic testing portfolio and expanding into pediatrics, rare diseases, immunology, and cardiology. With third-quarter 2024 results showing a 33% revenue increase, Tempus is positioned as a leader in AI-driven precision medicine, combining recent growth with strategic acquisitions to drive innovation in healthcare." /> <meta name="keywords" content="Tempus AI Ambry Genetics acquisition AI precision medicine genetic testing cancer screening rare diseases pediatrics cardiology immunology biotechnology genomic diagnostics hereditary cancer screening healthcare innovation Eric Lefkofsky Tempus revenue growth 2024 financial results genomics data services artificial intelligence healthcare technology patient care oncology insights Eric Lefkofsky SE Engine acquisition PARIS testing organoid biobank Tempus investor relations" />  <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:title" content="Tempus AI to Acquire Ambry Genetics for $600 Million"> <meta name="twitter:description" content="Tempus AI announced its acquisition of Ambry Genetics for $600 million, strengthening its genetic testing portfolio and expanding into pediatrics, rare diseases, immunology, and cardiology. With third-quarter 2024 results showing a 33% revenue increase, Tempus is positioned as a leader in AI-driven precision medicine, combining recent growth with strategic acquisitions to drive innovation in healthcare."> <meta name="twitter:image" content="https://www.biopharmatrend.com/files/blog/social/Tempus-Photo_Lab-3.jpg">  <meta property="og:type" content="article" /> <meta property="og:url" content="https://www.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/" /> <meta property="og:title" content="Tempus AI to Acquire Ambry Genetics for $600 Million" /> <meta property="og:description" content="Tempus AI announced its acquisition of Ambry Genetics for $600 million, strengthening its genetic testing portfolio and expanding into pediatrics, rare diseases, immunology, and cardiology. With third-quarter 2024 results showing a 33% revenue increase, Tempus is positioned as a leader in AI-driven precision medicine, combining recent growth with strategic acquisitions to drive innovation in healthcare." /> <meta property="article:published_time" content="2024-11-11T12:56:41+00:00"> <meta property="article:modified_time" content="2024-11-11T12:56:41+00:00"> <meta name="author" content="Roman Kasianov"> <meta property="og:image" content="https://www.biopharmatrend.com/files/blog/social/Tempus-Photo_Lab-3.jpg"> <script type="application/ld+json">{ "@context": "https://schema.org", "@type": "NewsArticle", "headline": "Tempus AI to Acquire Ambry Genetics for $600 Million", "datePublished": "2024-11-11T12:56:41+00:00", "dateModified": "2024-11-11T12:56:41+00:00", "description": "Tempus AI\nhas announced its\nacquisition\nof\nAmbry Genetics\n, from KONICA MINOLTA, INC.\nfor $600 million\n, comprising $375 million in cash and $225 million in shares. This strategic acquisition expands Tempus\u2019 capabilities in hereditary cancer screening and genetic testing, adding to its precision medicine offerings. Ambry Genetics, originally founded in 1999 by Charlie Dunlop in San Diego, was sold to Konica Minolta in 2017 for $1 billion.", "image": "https://www.biopharmatrend.com/files/blog/social/Tempus-Photo_Lab-3.jpg", "url": "https://www.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://www.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/" }, "publisher": { "@type": "Organization", "name": "BiopharmaTrend", "url": "https://www.biopharmatrend.com", "logo": { "@type": "ImageObject", "url": "https://www.biopharmatrend.com/static/img/bpt_logo.png" } }, "author": [ { "@type": "Person", "name": "Roman Kasianov", "url": "https://www.biopharmatrend.com/contributor/743/" } ] }</script> <style type="text/css"> .ap-chart-load svg { width: 100%; } .post-meta .author-linkein-icon { width: 1em; vertical-align: baseline; } .text-miniblock { display: inline-block; box-shadow: 0 0 6px -1px forestgreen; background: white; padding: 0.5rem; } .post .text-miniblock a { color: black; } .post .text-miniblock a:hover, .post .text-miniblock a:active { color: #333; text-decoration: underline; } .text-miniblock-right { float: right; margin: 0 0 1rem 1rem; max-width: 14rem; } .subscribe-block { background-color: deepskyblue; color: white; margin-top: 1.5rem; margin-bottom: 2rem; padding-top: 1.5rem; padding-bottom: 1.5rem; width: calc(50% + 100vw); padding-left: calc(50vw - 50%); padding-right: 50vw; margin-left: calc(50% - 50vw); position: relative; } .subscribe-block > .subscribe-inner { background-image: url('/files/subscription-bg.png'); background-position: right bottom; background-size: auto 120%; background-repeat: no-repeat; } .mobile-only { display: none; } @media screen and (max-width: 34em) { .text-miniblock-right { float: none; margin: 1rem 0; max-width: 100%; } .subscribe-block > .subscribe-inner { background-image: unset; } .mobile-only { display: block; } } </style> <link rel="shortcut icon" href="/static/favicon.ab1145f4d518.ico" /> <link rel="stylesheet" type="text/css" href="/static/css/main.6dead4e2266d.css" /> </head> <body> <div id="main-preheader"> <div class="container block-preheader"> <div id="logo-top"> <a href="/"><b>BioPharmaTrend</b></a>  </div> <div class="burger-container"> <div class="burger-button-container"> <button type="button" class="burger-button" onclick="document.documentElement.classList.toggle('blockfix');this.parentElement.parentElement.classList.toggle('active');"> <div class="burger-line burger-line-1"></div> <div class="burger-line burger-line-2"></div> <div class="burger-line burger-line-3"></div> </button> </div>  <div id="main-search-menu"> <div class="top-search"> <form action="/search/" class="top-search-form"> <button type="submit" class="btn btn-default"><i class="glyphicon glyphicon-search"></i></button> <input type="text" name="q" value="" size="10" class="form-control form-control-inline" required="" placeholder="e.g. 'quantum tech' or 'stem cell'"> <input type="hidden" name="section" value="insights"> </form> <span class="top-search-switcher button" onclick="this.parentElement.classList.toggle('active')"> <span class="glyphicon glyphicon-search"></span> <span class="glyphicon glyphicon-remove"></span> </span> </div> <span class="top-search-switcher button"> <span class="glyphicon glyphicon-search"></span> </span> </div>  <nav id="main-menu"> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/news/"><b>Latest News</b></a> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">All Topics <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/topic/bioeconomy-society/">Bioeconomy & Society</a></li> <li><a class="top-menu-link" href="/topic/ai-digital/">AI & Digital</a></li> <li><a class="top-menu-link" href="/topic/startups/">Startups & Deals</a></li> <li><a class="top-menu-link" href="/topic/neurotech/">NeuroTech</a></li> <li><a class="top-menu-link" href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a class="top-menu-link" href="/topic/synbio/">Biotech</a></li> <li><a class="top-menu-link" href="/topic/tools-methods/">Tools & Methods</a></li> <li><a class="top-menu-link" href="/topic/healthtech/">HealthTech</a></li> <li><a class="top-menu-link" href="/topic/aging-research/">Aging & Longevity</a></li> <li><a class="top-menu-link" href="/topic/contract-research/">Contract Research</a></li> <div class="sub-menu-margin"></div>  <li><a class="top-menu-link" href="/section/latest/">Latest insights</a></li> <li><a class="top-menu-link" href="/premium-content/">Premium Content</a></li> <div class="sub-menu-margin" style="border-bottom: 1px solid limegreen;"></div> <li><a class="top-menu-link" href="/knowledge-center/">Knowledge Center</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/interviews/"><b>Interviews</b></a> </div>  <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">Companies <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu">  <li><a class="top-menu-link" href="/m/marketplace/">Company Directory</a></li> <li><a class="top-menu-link" href="/section/interviews/">Interviews with Thought Leaders</a></li> <li><a class="top-menu-link" href="/section/case-studies/">Sponsored Case Studies</a></li> <li><a class="top-menu-link" href="/m/editor-tool/">Create Company Profile</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">More <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/about/">About Us</a></li> <li><a class="top-menu-link" href="/about/team/">Our Team</a></li> <li><a class="top-menu-link" href="/about/advisory-board/">Advisory Board</a></li> <li><a class="top-menu-link" href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a class="top-menu-link" href="/events/">Partner Events Calendar</a></li> <li><a class="top-menu-link" href="/advertising-media-kit/">Advertise with Us</a></li> <li><a class="top-menu-link" href="/contributor/">Write for Us</a></li> </ul> </div> </div> </nav> </div> <div id="main-user-actions">  <div class="mobile-menu-item"> <a href="/membership/" class="button-subscribe top-menu-link">Subscribe</a> </div>  <div class="mobile-menu-item last"> <a href="#" class="mobile-menu-item-title" rel="nofollow" title="Login/Join" onclick="document.getElementById('login-popup').classList.toggle('hidden')"> <span class="glyphicon glyphicon-log-in"></span> <span class="mobile-hide-m">Login/Join</span> </a> </div> </div> </div> </div> <div id="main-preheader-margin"></div> <div id="sencondary-menu-block"> <div class="container clearfix"> <nav> <ul class="text-center"> <li><a href="/topic/ai-digital/">AI & Digital</a></li> <li><a href="/topic/startups/">Startups & Deals</a></li> <li><a href="/topic/neurotech/">NeuroTech</a></li> <li><a href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a href="/topic/synbio/">Biotech</a></li> <li><a href="/topic/tools-methods/">Tools & Methods</a></li> </ul> </nav> </div> </div>  <div id="main-content" class="container"> <main id="content" class="col-lg-9 col-md-8 col-sm-12 col-xs-12"> <div class="mobile-only"> </div> <article id="post-1016" class="post "> <header> <h1>Tempus AI to Acquire Ambry Genetics for $600 Million</h1> </header> <footer class="post-meta"> <div class="tooltip"> <span class="glyphicon glyphicon-pencil"></span> by <a href="/contributor/743/">Roman Kasianov</a> </span>    <span style="white-space: nowrap;"> <span class="glyphicon glyphicon-folder-open"></span>   News </span> <div class="tooltip-text"> <div class="tooltip-close" onclick="this.parentElement.parentElement.classList.toggle('tooltip-show');"></div> <p><b>Disclaimer</b>: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com. <br> Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.</p> </div> </div> <div> <span class="glyphicon glyphicon-calendar" title="Published on"></span> <time datetime="2024-11-11">Nov. 11, 2024</time>    </em> </div> <div class="tags"> <b>Topics: </b> <a href="/topic/startups/">Startups & Deals</a>    </div> <div> <strong>Share: </strong>   <a target="_blank" rel="nofollow" href="https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Share in LinkedIn" src="/static/img/soc-in.7bc286fd757e.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://www.reddit.com/submit?url=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Share in Reddit" src="/static/img/soc-reddit.342e87a07115.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Share in X" src="/static/img/soc-x.3c80e8291cba.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://news.ycombinator.com/submitlink?u=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Share in Hacker News" src="/static/img/soc-y.587f16a5f3f3.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/&display=page"> <img alt="Share in Facebook" src="/static/img/soc-fb.3031a5a810f0.png" width="28" height="28" /></a>  <a target="_blank" rel="nofollow" href="mailto:?subject=Biopharmatrend.com&body=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Send by email" src="/static/img/soc-mail.41ce3608f438.png" width="28" height="28"></a>   |  <a href="/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/pdf/" target="_blank" rel="nofollow"> <span style="vertical-align: text-top; color: deepskyblue; font-size: 1.5em;" class="glyphicon glyphicon-print"></span></a> </div> </footer> <section> <p><a href="https://www.biopharmatrend.com/m/company/tempus/">Tempus AI</a> has announced its <a href="https://www.tempus.com/news/tempus-reports-third-quarter-2024-results-and-agreement-to-acquire-ambry-genetics/">acquisition</a> of <a href="https://www.ambrygen.com">Ambry Genetics</a>, from KONICA MINOLTA, INC.<strong> for $600 million</strong>, comprising $375 million in cash and $225 million in shares. This strategic acquisition expands Tempus’ capabilities in hereditary cancer screening and genetic testing, adding to its precision medicine offerings. Ambry Genetics, originally founded in 1999 by Charlie Dunlop in San Diego, was sold to Konica Minolta in 2017 for $1 billion.</p> <p>Ambry, headquartered in Aliso Viejo, California, will continue to operate as a wholly owned subsidiary of Tempus, retaining its employees and full testing menu. CEO Eric Lefkofsky explained that this acquisition supports Tempus' objective to provide comprehensive, continuous patient care:</p> <blockquote> <p>"It’s critical to us because we want to capture patients early, support them during treatment, and monitor their disease progression over time," he said, emphasizing the efficiency of partnering with a single, integrated lab solution.</p> </blockquote> <p>The purchase of Ambry follows <a href="https://investors.tempus.com/static-files/7aea7b14-291d-4962-a95f-bd372a056019">Tempus' acquisition of SEngine Precision Medicine</a>, founded by Dr. Carla Grandori, which brought in an organoid biobank and <a href="https://senginemedicine.com/paris-test">PARIS testing platform</a>. These recent acquisitions indicate Tempus’ strategic expansion into the immunotherapy testing space in precision medicine.</p> <p>The Ambry transaction, funded through a $300 million increase in short- and long-term debt, aligns with Tempus' plan to broaden its testing portfolio and enter new areas, including <strong>pediatrics, rare diseases, immunology, reproductive health, and cardiology.</strong></p> <p>Ambry is projected to generate $300 million in revenue in 2024, with a growth rate of over 25% annually, making it a promising financial addition for Tempus. The deal is expected to finalize in the first quarter of 2025.</p> <p>Tempus AI reported third-quarter 2024 results with a 33% revenue increase to $180.9 million, driven by significant growth in data, services, and genomics, alongside a narrowed adjusted EBITDA loss, projecting approximately $700 million in full-year revenue, a 32% annual growth.</p> <h6>Cover image: <a href="https://www.tempus.com/resources/media-kit/?post-search=&filter=images">Tempus</a></h6> <div class="product-list"> </div> <p> <b>Topics: </b> <a href="/topic/startups/">Startups & Deals</a>    </p> </section> </article> <div style="margin: 1em 0 2em; padding: 0.5em 0;"> <strong>Share: </strong>   <a target="_blank" rel="nofollow" href="https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Share in LinkedIn" src="/static/img/soc-in.7bc286fd757e.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://www.reddit.com/submit?url=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Share in Reddit" src="/static/img/soc-reddit.342e87a07115.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Share in X" src="/static/img/soc-x.3c80e8291cba.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://news.ycombinator.com/submitlink?u=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Share in Hacker News" src="/static/img/soc-y.587f16a5f3f3.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/&display=page"> <img alt="Share in Facebook" src="/static/img/soc-fb.3031a5a810f0.png" width="28" height="28" /></a>  <a target="_blank" rel="nofollow" href="mailto:?subject=Biopharmatrend.com&body=https%3A%2F%2Fwww.biopharmatrend.com/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"> <img alt="Send by email" src="/static/img/soc-mail.41ce3608f438.png" width="28" height="28"></a> </div> <div class="subscribe-block"> <div class="subscribe-inner"> <h3 style="line-height:1.5; font-weight: 900;"> <span style="font-weight: 900">Get Exclusive Insights Into Your Inbox</span> <br> <span style="font-weight: normal;">join 7000+ BPT insiders</span> </h3> <br> <div> <a style="font-size: 1.25em;width:17em; text-align: center; border-color: white; color: white; font-weight: 900" href="#" onclick="toggleMailingPopup(true)" class="btn">Subscribe</a> </div> </div> </div> </main> <aside id="main-sidebar" class="col-lg-3 col-md-4 col-sm-12 col-xs-12"> <section class="well"> <h4>Latest Articles</h4> <ul> <li><a href="/post/1029-novartis-expands-radiopharmaceutical-portfolio-with-745m-deal-with-ratio-therapeutics/">Novartis Expands Radiopharmaceutical Portfolio with $745M Deal with Ratio Therapeutics</a></li> <li><a href="/post/1024-immunai-and-teva-collaborate-to-advance-clinical-trials-in-oncology-and-immunology/">Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology</a></li> <li><a href="/post/1022-genesis-therapeutics-collaborates-with-nvidia-and-secures-additional-nventures-funding-to-accelerate-ai-driven-drug-discovery/">Genesis Therapeutics Collaborates with NVIDIA and Secures Additional NVentures Funding to Accelerate AI-Driven Drug Discovery</a></li> <li><a href="/post/1020-schrodinger-and-novartis-forge-23-billion-partnership-to-scale-computational-drug-discovery/">Schr枚dinger and Novartis Forge Partnership to Scale Computational Drug Discovery</a></li> <li><a href="/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/">Tempus AI to Acquire Ambry Genetics for $600 Million</a></li> <li><a href="/post/1012-uk-life-sciences-venture-capital-outperforms-general-market-british-business-bank-report/">UK Life Sciences Venture Capital Outperforms General Market: British Business Bank Report</a></li> </ul> </section> </aside> </div> <footer id="main-footer"><div class="container"> <div class="row"> <div class="col-12 col-sm-6 col-lg-3"> <h4 class="footer-logo"><span style="font-weight: 900">BiopharmaTrend</span>.com</h4> <div style="margin-bottom: 1.25em" class="footer-logo-slogan">Where Tech Meets Bio</div>  <div style="margin-bottom: 0.5em;"><a href="#main-footer" onclick="toggleMailingPopup(true)" style="color: lemonchiffon"> <img src="/static/img/sm-mail.a3210e82fe37.png" alt="mail" width="32" height="32" />  <b>Newsletter</b> </a></div> <div style="margin-bottom: 0.5em"><a href="https://www.linkedin.com/company/biopharmatrend-com/" rel="nofollow" target="_blank"> <img src="/static/img/sm-in.fb9ea368635d.png" alt="in" width="32" height="32" />  LinkedIn </a></div> <div style="margin-bottom: 0.5em"><a href="https://twitter.com/BiopharmaTrend" rel="nofollow" target="_blank"> <img src="/static/img/sm-x.9f3327271e1a.png" alt="x" width="32" height="32" />  X </a></div> <div style="margin-bottom: 0.5em"><a href="https://news.google.com/publications/CAAqBwgKMOaRugsw86zRAw?hl=en-US&gl=US&ceid=US:en" rel="nofollow" target="_blank"> <img src="/static/img/sm-gnews.ac9eb4674c84.png" alt="gnews" width="32" height="32" />  Google News </a></div> <div><a href="/rss/" rel="nofollow" target="_blank"> <img src="/static/img/sm-rss.bcd2cefd2eba.png" alt="rss" width="32" height="32" />  RSS Feed </a></div> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>About</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/about/">What we do</a></li> <li><a href="/editorial-calendar/">Editorial Calendar</a></li> <li><a href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a href="/terms-of-use/">Terms of Use</a></li> <li><a href="/privacy-policy/">Privacy Policy</a></li>  <li><a href="/about/disclaimer/">Disclaimer</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>We Offer</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/premium-content/"><b style="color: lemonchiffon">Premium Content</b></a></li> <li><a href="/m/marketplace/">BioTech Scout</a></li> <li><a href="/our-products/">Reports</a></li> <li><a href="/section/interviews/">Interviews</a></li> <li><a href="/events/">Partner Events</a></li> <li><a href="/section/case-studies/">Case Studies</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>Opportunities</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/membership/">Membership</a></li> <li><a href="/advertising-media-kit/">Advertise</a></li> <li><a href="/m/editor-tool/">Submit Company</a></li> <li><a href="/contributor/">Write for Us</a></li> <li><a href="/guest-blog/guidelines/">Author Guidelines</a></li> <li><a href="/a/contact/">Contact Us</a></li> </ul> </nav> </div> </div> <hr> <div class="text-right">© BPT Analytics LTD 2024</div> </div></footer> <div id="bpt-consent"><div class="container"> <div class="row"> <div class="col-12 col-md-6 col-lg-8"> We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our <a href="/cookies-policy/">cookies policy</a>. </div> <div class="col-12 col-md-6 col-lg-4 text-right"> <button class="btn btn-primary btn-sm" type="button" onclick="changeConsent('analytics')" style="white-space:unset">Agree</button> </div> </div> </div></div> <div id="login-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div class="popup-content" style="width: 25em;"> <form method="post" class="api-form" action="/a/login/?next=/post/1016-tempus-ai-to-acquire-ambry-genetics-for-600-million/"></form> </div> </div> <div id="subscription-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div id="subscription-popup-iframe" class="popup-content" style="width: 25em;"> </div> </div> <div id="scroll-top-pixel-anchor"></div> <button id="go-top" onclick="window.scrollTo({top: 20, left: 0, behavior: 'smooth'})">^</button> <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script> <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.4.1/js/bootstrap.min.js"></script> <script src="/static/js/main.df923d2272d3.js"></script> <script type="text/javascript"> if ( "IntersectionObserver" in window && "IntersectionObserverEntry" in window && "intersectionRatio" in window.IntersectionObserverEntry.prototype ) { let observer = new IntersectionObserver(entries => { if (entries[0].boundingClientRect.y < 0) { document.body.classList.add("scroll-top"); } else { document.body.classList.remove("scroll-top"); } }); observer.observe(document.getElementById("scroll-top-pixel-anchor")); } </script> </body> </html>

CINXE.COM

Tempus AI to Acquire Ambry Genetics for $600 Million